<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045461</url>
  </required_header>
  <id_info>
    <org_study_id>LMU-DOLPHIN-1</org_study_id>
    <secondary_id>CDR0000256532</secondary_id>
    <secondary_id>EU-20220</secondary_id>
    <nct_id>NCT00045461</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer</brief_title>
  <official_title>A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several&#xD;
      degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor&#xD;
      cells. It is not yet known if chemotherapy is more effective with or without whole-body&#xD;
      hyperthermia therapy in treating gynecologic cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II/III trial to compare the effectiveness of chemotherapy with or&#xD;
      without whole-body hyperthermia in treating patients who have recurrent ovarian epithelial,&#xD;
      fallopian tube, or peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the time to progressive disease in patients with recurrent ovarian epithelial,&#xD;
           fallopian tube, or extraovarian peritoneal cancer treated with carboplatin and&#xD;
           ifosfamide with or without whole body hyperthermia.&#xD;
&#xD;
        -  Compare the response rate, duration of response, and survival time of patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the effect on the presence of disseminated tumor cells in bone marrow in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Assess quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a phase II safety and efficacy study followed by a phase III randomized,&#xD;
      open-label, multicenter study.&#xD;
&#xD;
        -  Phase II: Patients receive ifosfamide IV over 1 hour and carboplatin IV over 20 minutes&#xD;
           on day 1. Patients also undergo whole body hyperthermia for at least 1 hour on day 1.&#xD;
           Treatment repeats every 28 days for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Phase III (after successful treatment of 15 patients in phase II): Patients are&#xD;
           stratified according to disease-free interval (6-12 months vs more than 12 months),&#xD;
           measurable disease (bidimensionally measurable vs measurable by other clinical means),&#xD;
           and disease recurrence (first recurrence vs second or greater recurrence). Patients are&#xD;
           randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive ifosfamide, carboplatin, and whole body hyperthermia as in&#xD;
                phase II.&#xD;
&#xD;
             -  Arm II: Patients receive ifosfamide and carboplatin as in arm I.&#xD;
&#xD;
             -  In both arms, treatment repeats every 28 days for 6 courses in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed before each course, 4 weeks after the last course, and then every&#xD;
      3 months for 2 years.&#xD;
&#xD;
      Patients are followed at 4 weeks and then every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for phase II of this study. A total&#xD;
      of 226 patients (113 per treatment arm) will be accrued for phase III of this study within 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2000</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progressive disease</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on the presence of disseminated tumor cells in bone marrow</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
  </primary_outcome>
  <enrollment type="Anticipated">241</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermia treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or extraovarian&#xD;
             peritoneal cancer&#xD;
&#xD;
               -  Recurrent disease (any FIGO stage)&#xD;
&#xD;
               -  Not amenable to curative surgery or radiotherapy alone&#xD;
&#xD;
          -  Failed prior primary platinum-based therapy at least 6 months after therapy&#xD;
             discontinuation&#xD;
&#xD;
          -  Measurable lesion by CT scan, MRI, chest x-ray, or sonography&#xD;
&#xD;
               -  Physical examination allowed for documenting lymph node and skin metastases&#xD;
&#xD;
               -  Physical gynecological examination allowed for well-defined palpable tumor&#xD;
                  lesions&#xD;
&#xD;
               -  Increase in CA 125 without any measurable tumor is not acceptable as indication&#xD;
                  of recurrence&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  No tumor of borderline malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 24 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No chronic or acute renal failure&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiovascular function sufficient for hyperthermia treatment by stress-ECG&#xD;
&#xD;
          -  No cardiomyopathy with impaired ventricular function&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No cardiac arrhythmias influencing LVEF and requiring medication&#xD;
&#xD;
          -  No myocardial infarction or angina pectoris within the past 6 months&#xD;
&#xD;
          -  No uncontrolled arterial hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Pulmonary function sufficient for hyperthermia treatment by pulmonary function tests&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No untreated endocrinological disease (e.g., hyperthyroidism or diabetes mellitus)&#xD;
&#xD;
          -  No other primary malignancy except carcinoma in situ of the cervix or adequately&#xD;
             treated basal cell skin cancer&#xD;
&#xD;
          -  No contraindication against hyperthermia treatment (e.g., photodermatosis, history of&#xD;
             malignant hyperthermia, or claustrophobia)&#xD;
&#xD;
          -  No hypersensitivity to carboplatin, ifosfamide, or any other study medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent cytotoxic or other antineoplastic therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  Concurrent steroid antiemetics allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 year since prior radiotherapy (tumoricidal dose) of the pelvis&#xD;
&#xD;
          -  Concurrent palliative local radiotherapy for painful (nonprogressive) existing lesion&#xD;
             is allowed if other measurable sites are present&#xD;
&#xD;
          -  No concurrent radiotherapy to a second existing lesion&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior form of hyperthermic therapy&#xD;
&#xD;
          -  At least 3 weeks since other medications as part of another clinical study&#xD;
&#xD;
          -  At least 3 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 6 weeks since prior betablockers&#xD;
&#xD;
          -  No concurrent photosensitizing drugs&#xD;
&#xD;
          -  No concurrent betablockers&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sommer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Hildebrandt, MD</last_name>
      <phone>49-30-450-553-636</phone>
      <email>bert.hildebrandt@chu-ite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Jaeger, MD</last_name>
      <phone>49-69-7601-3380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Hegewisch-Becker, MD</last_name>
      <phone>49-40-428-033-971</phone>
      <email>hegewisch@uke.uni-hamburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik - Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Bakhshandeh-Bath, MD</last_name>
      <phone>0049-451-500-2316</phone>
      <email>bakhshan@medinf.mu_luebeck.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Trostberg</name>
      <address>
        <city>Trostberg</city>
        <zip>D-83308</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Biedermann, MD</last_name>
      <phone>0862-11-87-5020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peterfy Korhaz Szulo-Nobeteg Oztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Kornya, MD</last_name>
      <phone>36-1-322-3450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneke M. Westermann, MD, PhD</last_name>
      <phone>31-20-566-5955</phone>
      <email>a.m.westermann@amc.uva.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IV primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

